Antacid Medicines Improve Overall Survival in Head and Neck Cancer
the Cancer Therapy Advisor take:
According to a new study published in the journal Cancer Prevention Research, researchers from the University of Michigan Comprehensive Cancer Center in Ann Arbor, Michigan, have found that patients with head and neck cancer who used antacids, like proton pump inhibitors and histamine 2 receptor antagonists, to treat heart burn and indigestion had better overall survival rates compared with those who did not use them.
For the study, researchers analyzed data of 596 patients treated for head and neck cancer. Of those, more than two-thirds took histamine 2 receptor antagonists, proton pump inhibitors, or both.
Results showed that among those that took proton pump inhibitors, such as omeprazole, esomeprazole, and pantoprazole, had a 45% decreased mortality risk compared with those who did not take the medications.
Patients who took histamine 2 receptor antagonists, which include cimetidine, ranitidine, and famotidine, had a 33% decreased mortality risk compared with those did not take the antacids.
Patients with head and neck cancer who are treated with chemotherapy and radiation often experience reflux, leading to wide use of antacids as a treatment for the adverse effect; however, the findings suggest that antacids like proton pump inhibitors and histamine 2 blockers also have a positive impact on overall survival.
Antacids had better overall survival rates compared with those who did not use them.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Immunotherapy in Glioblastoma: Peaks and Pits
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Opinion: Understanding the FDA's Take on Cannabidiol
- OS and PFS End Points Not Met in Phase 3 Trial of Pembrolizumab in Advanced HCC
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Evidence of the Role of Circulating Insulin in Renal Cell Carcinoma Risk
- Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
- American Society of Breast Surgeons Recommends Genetic Testing for All Patients With Breast Cancer